CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

von Willebrand Factor [recombinant]

Last Updated: May 13, 2020
Result type: Reports
Project Number: ST0639-000
Product Line: Common Drug Review

Generic Name: von Willebrand Factor [recombinant]

Brand Name: Vonvendi

Manufacturer: Shire Pharma Canada ULC, now part of Takeda

Indications: von Willebrand disease, adults, treatment and perioperative management

Manufacturer Requested Reimbursement Criteria1: Indicated for: Treatment and Control of bleeding episodes in adults (age 18) diagnosed with von Willebrand Disease (VWD). Perioperative management of bleeding in adults (age 18) diagnosed with VWD

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule E

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input open January 02, 2020
Call for patient input closed February 21, 2020

- Patient input submission received from the Canadian Hemophilia Society

Submission received April 29, 2020
Submission accepted May 13, 2020
Review initiated May 14, 2020
Draft CADTH review report(s) provided to sponsor for comment July 29, 2020
Deadline for sponsors comments August 10, 2020
CADTH responses on draft review report(s) provided to sponsor September 03, 2020
Expert committee meeting (initial) September 16, 2020
Draft recommendation issued September 28, 2020
September 30, 2020